Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:NVO NASDAQ:PLTR NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeNVONovo Nordisk A/S$50.92+0.0%$65.40$45.05▼$139.74$227.27B0.6326.16 million shs12.53 million shsPLTRPalantir Technologies$181.02-1.8%$150.04$29.31▼$190.00$435.10B2.660.05 million shs53.32 million shsUTHRUnited Therapeutics$312.06+0.8%$295.25$266.98▼$417.82$13.97B0.57676,653 shs586,994 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceNVONovo Nordisk A/S+0.04%+4.42%-24.36%-20.87%-62.12%PLTRPalantir Technologies-1.82%-0.65%+21.83%+39.76%+484.12%UTHRUnited Therapeutics+0.76%+4.22%+6.42%+2.20%-3.65%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationNVONovo Nordisk A/S4.6771 of 5 stars4.05.02.50.03.10.03.1PLTRPalantir Technologies2.1119 of 5 stars2.03.00.00.03.31.71.3UTHRUnited Therapeutics4.9353 of 5 stars3.34.00.04.64.23.32.5Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceNVONovo Nordisk A/S 2.07Hold$83.7564.48% UpsidePLTRPalantir Technologies 2.09Hold$136.61-24.53% DownsideUTHRUnited Therapeutics 2.69Moderate Buy$382.0022.41% UpsideCurrent Analyst Ratings BreakdownLatest PLTR, NVO, and UTHR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/14/2025UTHRUnited TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight8/13/2025NVONovo Nordisk A/SBNP ParibasSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral8/13/2025NVONovo Nordisk A/SBNP Paribas ExaneSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderperform ➝ Neutral$54.008/13/2025UTHRUnited TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$385.00 ➝ $415.008/6/2025PLTRPalantir TechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$90.00 ➝ $141.008/5/2025PLTRPalantir TechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$182.008/5/2025NVONovo Nordisk A/SUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral8/5/2025PLTRPalantir TechnologiesCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$158.00 ➝ $177.008/5/2025PLTRPalantir TechnologiesDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$115.00 ➝ $170.008/5/2025PLTRPalantir TechnologiesMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetEqual Weight ➝ Equal Weight$98.00 ➝ $155.008/5/2025PLTRPalantir TechnologiesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetOutperform ➝ Outperform$160.00 ➝ $200.00(Data available from 8/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookNVONovo Nordisk A/S$42.12B5.40$3.90 per share13.05$5.73 per share8.89PLTRPalantir Technologies$2.87B149.08$0.09 per share1,998.38$2.55 per share70.99UTHRUnited Therapeutics$2.88B4.89$28.60 per share10.91$159.04 per share1.96Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateNVONovo Nordisk A/S$14.64B$3.6413.9910.931.7535.60%78.64%24.51%N/APLTRPalantir Technologies$462.19M$0.30603.42532.4110.3922.18%10.75%8.71%11/3/2025 (Estimated)UTHRUnited Therapeutics$1.20B$25.6212.1811.354.6940.36%18.73%16.49%10/29/2025 (Estimated)Latest PLTR, NVO, and UTHR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025 NVONovo Nordisk A/S$0.93$0.97+$0.04$0.91$77.51 billion$11.69 billion8/4/2025Q2 2025PLTRPalantir Technologies$0.14$0.16+$0.02$0.13$939.29 million$1.00 billion7/30/2025Q2 2025UTHRUnited Therapeutics$6.80$6.41-$0.39$6.41$802.13 million$798.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthNVONovo Nordisk A/S$1.643.22%N/A45.05%N/APLTRPalantir TechnologiesN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ALatest PLTR, NVO, and UTHR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/7/2025NVONovo Nordisk A/Ssemi-annual$0.41192.4%8/18/20258/18/20258/26/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioNVONovo Nordisk A/S0.520.780.56PLTRPalantir TechnologiesN/A6.326.32UTHRUnited TherapeuticsN/A7.266.94Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipNVONovo Nordisk A/S11.54%PLTRPalantir Technologies45.65%UTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipNVONovo Nordisk A/S0.07%PLTRPalantir Technologies9.23%UTHRUnited Therapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableNVONovo Nordisk A/S77,3494.47 billion4.46 billionOptionablePLTRPalantir Technologies3,9362.36 billion2.14 billionOptionableUTHRUnited Therapeutics1,30545.11 million40.46 millionOptionablePLTR, NVO, and UTHR HeadlinesRecent News About These CompaniesUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $415.00 at UBS Group1 hour ago | marketbeat.comPrudential PLC Acquires 4,094 Shares of United Therapeutics Corporation (NASDAQ:UTHR)4 hours ago | marketbeat.comUBS Group Increases United Therapeutics (NASDAQ:UTHR) Price Target to $415.00August 15 at 2:56 AM | americanbankingnews.comAnalysts Set United Therapeutics Corporation (NASDAQ:UTHR) PT at $379.69August 15 at 2:41 AM | americanbankingnews.comNuveen LLC Acquires Shares of 270,975 United Therapeutics Corporation (NASDAQ:UTHR)August 14 at 5:15 AM | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Increases Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)August 14 at 4:32 AM | marketbeat.comCitigroup Inc. Lowers Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)August 14 at 4:24 AM | marketbeat.comDeutsche Bank AG Cuts Stake in United Therapeutics Corporation (NASDAQ:UTHR)August 14 at 3:49 AM | marketbeat.comUnited Therapeutics price target raised to $415 from $385 at UBSAugust 13 at 11:58 AM | msn.com5 Insightful Analyst Questions From United Therapeutics’s Q2 Earnings CallAugust 13 at 6:57 AM | finance.yahoo.comUTHR Q2 Deep Dive: Tyvaso DPI Drives Growth Amid Pipeline and Competitive UncertaintyAugust 13 at 6:57 AM | finance.yahoo.comUnited Therapeutics Corporation (NASDAQ:UTHR) Shares Sold by Charles Schwab Investment Management Inc.August 13 at 3:43 AM | marketbeat.comLiquidia Shoots Higher As Yutrepia Launch Kicks Off Amid United Patent BattleAugust 12 at 4:08 PM | msn.comUnited Therapeutics’ Promising Phase 3 Study on Inhaled Treprostinil for Pulmonary FibrosisAugust 12 at 12:10 PM | tipranks.comLiquidia Corporation Reports Strong Early Adoption of YUTREPIA™ with Over 900 Patient Prescriptions and Positive Interim Data from ASCENT TrialAugust 12 at 7:07 AM | quiverquant.comQVanguard Group Inc. Increases Position in United Therapeutics Corporation (NASDAQ:UTHR)August 12 at 4:04 AM | marketbeat.comPNC Financial Services Group Inc. Grows Stock Holdings in United Therapeutics Corporation (NASDAQ:UTHR)August 12 at 3:45 AM | marketbeat.comXTX Topco Ltd Invests $313,000 in United Therapeutics Corporation (NASDAQ:UTHR)August 12 at 3:27 AM | marketbeat.comLPL Financial LLC Has $7.78 Million Stock Position in United Therapeutics Corporation (NASDAQ:UTHR)August 12 at 3:26 AM | marketbeat.comUnited Therapeutics Corporation (NASDAQ:UTHR) Given Consensus Rating of "Moderate Buy" by BrokeragesAugust 12 at 2:59 AM | marketbeat.comASR Vermogensbeheer N.V. Invests $378,000 in United Therapeutics Corporation (NASDAQ:UTHR)August 11, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesTrump GLP-1 Pilot Program Could Boost Novo Nordisk & Eli LillyBy Jordan Chussler | August 9, 2025Palantir Stock Gains Firepower From Pentagon AI DealsBy Chris Markoch | July 29, 2025Novo Nordisk Stock Sinks—But Is a Bottom Finally In?By Chris Markoch | August 5, 2025Palantir Bulls and Bears Set for an August Showdown By Chris Markoch | July 22, 2025AbbVie Stock Eyes Breakout as Pipeline and Profits GrowBy Chris Markoch | July 31, 2025PLTR, NVO, and UTHR Company DescriptionsNovo Nordisk A/S NYSE:NVO$50.92 +0.02 (+0.04%) Closing price 08/14/2025 03:59 PM EasternExtended Trading$51.36 +0.44 (+0.86%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.Palantir Technologies NASDAQ:PLTR$181.02 -3.35 (-1.82%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$180.18 -0.84 (-0.46%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates under the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.United Therapeutics NASDAQ:UTHR$312.06 +2.34 (+0.76%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$310.25 -1.81 (-0.58%) As of 09:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Deere’s Sell-Off Could Be a Long-Term Buying Chance Cisco Systems: The Only AI Stock Income Investors Need to Own Gartner’s RSI Just Sank to 11: That’s a Setup You Can’t Ignore How Did Peter Thiel-Backed Crypto Exchange Bullish's IPO Go? Mercury Systems Up 27%: Financials Send Investors a Clear Signal Brinker Serves Up Earnings Beat, Sidesteps Cost Pressures CAVA’s Honeymoon Ends With a 16% Stock Drop Rigetti Stock: A Long-Term Quantum Play Facing Short-Term Tests Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access